Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06444594 · ClinicalTrials.gov registry record · Early Phase 1
Transient Receptor Potential Channels
A Early Phase 1 study of Aging, sponsored by Penn State University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06444594: Recruiting Early Phase 1 study of Aging, sponsored by Penn State University.
NCT06444594 is a Early Phase 1 study of Aging that is actively recruiting participants, run by Penn State University. The registered enrollment target is 45 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06444594, a Early Phase 1 study of Aging, is actively recruiting participants, sponsored by Penn State University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
Neurovascular signaling in the skin associated with stimulation of the transient receptor potential (TRP) channels. These channels are stimulated by both temperature and naturally occurring bioactive agents found in mint, chili peppers, garlic, etc. The aim of the study is to examine how topically applied TRP channel agonists including menthol, capsaicin and camphor impact neurovascular responses in the skin.
Conditions Studied
Interventions
- DRUG TRPM8 Agonist
- DRUG TRPV1 Agonist
- DRUG TRPV4 Agonist
- DRUG TRPM8, TRPV4, TRPV1 Agonists
- OTHER Vehicle gel
Study Locations (1)
Pennsylvania
- Noll Laboratory - University Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-07-17 |
| Est. Completion | 2026-12-31 |
| Phase | Early Phase 1 |
What NCT06444594 shows while recruiting
NCT06444594 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Aging appearing as the primary indexed condition, and to 5 interventions - of which TRPM8 Agonist is the first listed.
NCT06444594 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06444594 about?
NCT06444594 is a clinical study titled "Transient Receptor Potential Channels". Neurovascular signaling in the skin associated with stimulation of the transient receptor potential (TRP) channels. These channels are stimulated by both temperature and naturally occurring bioactive agents found in mint, chili peppers, garlic, etc. The aim of the study is to examine how topically a...
What is the current status of trial NCT06444594?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 45 participants. The study started on 2024-07-17. Estimated completion is 2026-12-31.
What conditions does trial NCT06444594 study?
This clinical trial studies the following conditions: Aging.
What interventions are being tested in trial NCT06444594?
The interventions under investigation include: TRPM8 Agonist (DRUG), TRPV1 Agonist (DRUG), TRPV4 Agonist (DRUG), TRPM8, TRPV4, TRPV1 Agonists (DRUG), Vehicle gel (OTHER).
Who is sponsoring clinical trial NCT06444594?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06444594 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06444594's enrollment target sits among peer trials
45 166th of 262 higher than 96 of 262 other Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gene Expression Changes In Young and Geriatric Skin
RECRUITING · Early Phase 1
-
Examining the Effects of Theta Burst TMS on Brain Connectivity and Balance Ability in Older Adults With Balance Problems
RECRUITING · Early Phase 1
-
Early Neurovascular Adaptations in Aging Women
RECRUITING · Early Phase 1
-
Heat, Microvascular Function and Aging
RECRUITING · Early Phase 1
-
Angiotensin-(1-7) Cardiovascular Effects in Aging
RECRUITING · Early Phase 1
-
Effects of Nicotine and Attention on Frequency Tuning in Auditory Cortex
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI